Screener
Aquestive Therapeutics, Inc. AQST Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Aquestive Therapeutics, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001398733-26-000042
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| R&D other expenses: | ||||
| Personnel costs1 | 2,181 | 2,218 | 4,423 | 4,350 |
| Other2 | 574 | 493 | 893 | 1,039 |
| Total Research and Development Expenses | 3,962 | 4,105 | 8,166 | 9,466 |
| Selling expenses: | ||||
| Personnel costs3 | 1,730 | 608 | 3,374 | 1,302 |
| Other4 | 444 | 2,912 | 721 | 5,174 |
| Total Selling expenses | 2,174 | 3,520 | 4,095 | 6,476 |
Item 1. FINANCIAL STATEMENTS (Unaudited)
FAQ
- What is Aquestive Therapeutics, Inc.'s business segments — R&D?
- Aquestive Therapeutics, Inc. (AQST) reported business segments — R&D of $3.96M in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s business segments — R&D changed year-over-year?
- Aquestive Therapeutics, Inc.'s business segments — R&D decreased by 3.5% year-over-year, from $4.11M to $3.96M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s business segments — R&D?
- Over 2 years (2023 to 2025), Aquestive Therapeutics, Inc.'s business segments — R&D has grown at a 14.5% compound annual growth rate (CAGR), from $13.1M to $17.19M.
- What does business segments — R&D mean?
- Captures the expenditures dedicated to the discovery, clinical development, and regulatory advancement of the segment's pharmaceutical pipeline. This investment is critical for long-term value creation and future product commercialization. It reflects the company's commitment to innovation and its strategic focus on addressing unmet medical needs.
Ask your AI about Aquestive Therapeutics, Inc.'s business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude